A Phase 1 Study of SSGJ-709 in Patients With Advanced Malignant Tumors
NCT 07016490 Brief Summary This study is an open-label phase I study…
Read more arrow_forwardNCT 07016490 Brief Summary This study is an open-label phase I study…
Read more arrow_forwardNCT 04801095 Brief Summary This study evaluates the safety, tolerability, pharmacokinetics, pharmacodynamics,…
Read more arrow_forwardNCT 06384352 Brief Summary This is a multicenter, open-label, Phase 1 study.…
Read more arrow_forwardNCT 06815575 Brief Summary This is a multi-centre, two-part, open-label, phase 1,…
Read more arrow_forwardNCT 05332574 Brief Summary This is a Phase 1/2 study of GB263T…
Read more arrow_forwardNCT 05981703 Brief Summary This is an open-label, multicenter, and nonrandomized dose…
Read more arrow_forwardNCT 05094336 Brief Summary The primary objective of Parts 1 and 2…
Read more arrow_forwardNCT 06669975 Brief Summary This is a Phase 1/2, multi-regional, multi-center, open-label,…
Read more arrow_forwardNCT 06130553 Brief Summary This is a first time in human (FTiH)…
Read more arrow_forwardNCT 05381909 Brief Summary This study aims to understand how safe and…
Read more arrow_forward